<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="267">
  <stage>Registered</stage>
  <submitdate>10/08/2001</submitdate>
  <approvaldate>10/08/2001</approvaldate>
  <nctid>NCT00022516</nctid>
  <trial_identification>
    <studytitle>Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer</studytitle>
    <scientifictitle>Low-dose Cytotoxics as "Anti-angiogenesis Treatment" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym>22-00</trialacronym>
    <secondaryid>IBCSG-22-00</secondaryid>
    <secondaryid>CDR0000068827</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cyclophosphamide
Treatment: drugs - Methotrexate

No Intervention: No-CM - No further chemotherapy following standard adjuvant chemotherapy.

Experimental: CM-Maintenance - 12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)


Treatment: drugs: Cyclophosphamide
50 mg/day orally continuously for 1 year

Treatment: drugs: Methotrexate
2.5 mg twice/day orally days 1 and 2 of every week for 1 year

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free Survival - Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow-up.</outcome>
      <timepoint>5-year estimates, reported at a median follow-up of 6.9 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.</outcome>
      <timepoint>5-year estimates, reported at a median follow-up of 6.9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distant Recurrence-free Interval - Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free Interval is defined as the time from randomization to invasive breast cancer recurrence at distant site, or invasive contralateral breast cancer; or censored at date of last follow up.</outcome>
      <timepoint>5-year estimates, reported at a median follow-up of 6.9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Breast Cancer-free Interval - Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up.</outcome>
      <timepoint>5-year estimates, reported at a median follow-up of 6.9 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage I, II, or III breast cancer

               -  T1-3, N0-2, M0

                    -  Patients with sentinel node biopsy positive disease must have undergone
                       axillary dissection

                    -  Tumor must be confined to the breast without detected metastases elsewhere

               -  T4 disease with minimal dermal invasion allowed

               -  No T4 disease with ulceration of skin, infiltration of skin (except
                  pathologically minimal dermal involvement), peau d'orange, or inflammatory breast
                  cancer

          -  No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite
             breast that has not been proven benign

          -  No distant metastases

               -  No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan
                  showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or CT

          -  Must have undergone prior total mastectomy OR breast-conserving procedure (e.g.,
             lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with
             radiotherapy planned

               -  Patients must begin or have begun an approved induction chemotherapy regimen
                  within 8 weeks after definitive surgery

          -  Negative surgical margins

          -  Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node
             biopsy

          -  Known HER2 status by immunohistochemistry or fluorescence in situ hybridization

          -  Hormone receptor status:

               -  Estrogen and progesterone receptor negative

                    -  Less than 10% positive tumor cells by immunohistochemistry

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Sex:

          -  Not specified

        Menopausal status:

          -  Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no
             prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR

          -  Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since
             LMP without prior hysterectomy (OR age 50 and over)

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 3,000/mm3

          -  Platelet count greater than 100,000/mm3

        Hepatic:

          -  See Disease Characteristics

          -  Bilirubin less than 2.0 mg/dL

          -  ALT less than 1.5 times upper limit of normal OR AST less than 60 IU/L

        Renal:

          -  Creatinine less than 1.2 mg/dL

        Other:

          -  Not pregnant or lactating within the past 6 months

          -  Fertile patients must use effective barrier contraception

          -  No other prior or concurrent malignancy except adequately treated basal or squamous
             cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or
             ipsilateral in situ breast carcinoma

          -  No psychiatric or addictive disorders that would preclude study

          -  No non-malignant systemic disease that would preclude study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Prior trastuzumab (Herceptin) allowed

        Chemotherapy:

          -  See Disease Characteristics

          -  No prior adjuvant or neoadjuvant chemotherapy for breast cancer

        Endocrine therapy:

          -  No prior endocrine therapy for breast cancer or prevention

          -  No prior tamoxifen or raloxifene for breast cancer

        Radiotherapy:

          -  No prior radiotherapy for breast cancer except primary irradiation

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No prior preventative therapy for breast cancer</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>120</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1086</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Tweed Heads Hospital - Tweed Heads</hospital>
    <hospital>Queen Elizabeth Hospital - Adelaide</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Maroondah Hospital - East Ringwood</hospital>
    <hospital>Murray Valley Private Hospital and Cancer Treatment Centre - Wodonga</hospital>
    <hospital>Christchurch Hospital - Christchurch</hospital>
    <postcode>2485 - Tweed Heads</postcode>
    <postcode>5011 - Adelaide</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3135 - East Ringwood</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode>1 - Christchurch</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Valparaiso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Biella</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Carpi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rimini</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Nigeria</country>
      <state>Ibadan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Aarau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bellinzona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Chur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Rheinfelden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St. Gallen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Thun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>International Breast Cancer Study Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, phase III trial was designed to test the efficacy of a low-dose
      chemotherapy-maintenance regimen, hypothesized to have anti-angiogenic activity, administered
      following standard chemotherapy in patients with early breast cancer whose tumors are hormone
      receptor negative.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00022516</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Marco Colleoni, MD</name>
      <address>European Institute of Oncology</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>